



INVESTOR PRESENTATION

NOVEMBER 2021



Positioning for Growth

(ASX: RHT)

DISCLAIMER

This presentation has been prepared by Resonance Health Ltd ("Resonance Health" or "Company") and may contain forward-looking statements that are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health's products and services.

These forward looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.

This presentation does not constitute or form part of an offer of securities or a solicitation of invitation to buy or apply for securities, nor may it or any part of it form the basis of, or be relied on in any connection with any contract or commitment. The information in this presentation does not take into account the objectives, financial situation or particular needs of any person. Nothing contained in this presentation constitutes investment, legal, tax, or other advice. Potential investors should make their own decisions whether to invest in Resonance Health shares based on their own enquiries and are advised to seek appropriate independent advice. This presentation does not, and does not purport to, contain all the information prospective investors in Resonance Health would desire or require in reaching an investment decision.

To the maximum extent possible by law, none of Resonance Health, their officers, directors, employees, associates, or agents, nor any other person's accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any error or omissions in it.



ASX: RHT

- Australian medical technology company
- Early adopter of AI in medical imaging
- Gold standard in LIC with FerriScan
- Products and services sold in over 500 centres
- Strong IP position, several patents
- Supplemented by global channel partners
- Six regulatory cleared medical devices
- Two regulatory cleared AI medical devices
- Recent transitional period completed

"

Resonance Health is a global leader in the diagnosis and measurement of iron or fat in human organs, including the liver, heart, spleen, and brain.

"

Mission

To develop innovative healthcare products and services, to work diligently to deliver the highest quality products for customers and patients, and to operate with integrity and excellence in driving growth for shareholders.

Values

- Innovation
- Integrity
- Leadership
- Service
- Quality

Core Business

Resonance Health is an Australian medical-technology company with several regulatory cleared and deployed medical products related to iron and fat in human organs and a high-impact pipeline of new, near, medium, and long term research and development products.

PRESENTATION OUTLINE


1. New Global Salesforce

2. Introducing LiverSmart™

3. Prolific (and growing) Diseases

4. High Impact Innovation and R&D

ASX	RHT(* at 24/11/21)
Share price	0.12*
Shares on issue	461.1m
Market Capitalisation	\$55.33m*
Cash at Bank	\$8.4m (30/9)
Enterprise Value	\$63.73m*
Top 20 Shareholders	50.2%
Board & Management	20.3%




1. NEW GLOBAL SALESFORCE

Key Salesforce Initiatives


- Activating KOLs
- Clinical Trials (High Priority)
- Conference Participation
- Disciplined CRM Approach
- International Disease Advocates
- Penetrating New Markets
- Supplementing Channel Partners
- USA Reimbursement

REVENUE BY PRODUCT (FY 20/21)



■ FerriScan
■ Cardiac T2*
■ Liver Fat
■ Other

REVENUE BY REGION (FY 20/21)




■ USA
■ Great Britain
■ Canada
■ Europe
■ ANZ
■ Asia
■ Middle East
■ Rest of World

“Revenue is currently derived mainly from Resonance Health legacy products in well-established developed markets, with opportunity lying in much larger developing markets that have been made accessible by our new AI solutions.”

- Mitchell Wells, Managing Director

NEW MARKETS TARGETED

New AI devices enable new market penetration



Sales Personnel

Australia	2
Germany	1
India	2
South Korea	1
UK	2
USA	3
Total	11

2. INTRODUCING LIVERSMART™



A Multiparametric Analysis of
Liver Tissue Composition
Combining FerriSmart and HepaFat-AI

Report No: EzNWa4XxhYrABGruNMZ8XQ
Patient ID: 10054136-000017
Name: 10054136-000017
Birth Date:

Scan Date: 12 Aug 2021
Analysis Date: 28 Oct 2021
Referrer:
MRI Center:

SUMMARY OF RESULTS

Average Liver Iron Concentration

2.0 mg/g dry tissue **37 mmol/kg dry tissue**
(95% CI: 1.5 - 2.8) (95% CI: 26.6 - 50.2)
(NR: 0.17 - 1.8) (NR: 3 - 33)

For further details, see the Liver Iron Concentration Report

Liver Fat Assessment

	Result	95% CI (Confidence interval)	Normal Range
VLFF (Volumetric Liver Fat Fraction)	2.8%	2.2 - 3.6	0 - 4.1
PDFF (Proton Density Fat Fraction)	3.3%	2.6 - 4.2	0 - 4.8
Steatosis Grade	0		0

For further details, see the Liver Fat Assessment Report

If you have any questions on the current analysis and/or slice selected, please contact Resonance Health at support@resonancehealth.com

Resonance Health Analysis Services Pty Ltd CONFIDENTIAL www.resonancehealth.com

Applying to FDA for US Regulatory Clearance

AI automatically analyses MRI images and reports:

- Liver Iron Concentration (LIC)
- Proton Density Fat Fraction (PDFF)
- Volumetric Liver Fat Fraction (VLFF)
- Steatosis Grade
- Illustrative Liver Fat Distribution Map

Other Features:

- AI enables faster turnaround and scalability
- Appears to fulfil new US CPT Code requirements
- US CPT Codes will assist widespread USA reimbursement

"LiverSmart combines two of our existing regulatory-cleared products, FerriSmart® and HepaFat-AI®, into a single MRI session, avoiding the need for multiple MRI appointments, and delivering a more complete and comprehensive assessment of a person's liver."

Instead of obtaining individual FerriSmart® and HepaFat-AI® reports via separate scanner sessions, which adds to cost and inconvenience, patients and clinicians will soon be able to obtain both analyses at the same time with one referral, and in one consolidated report."

- Wenjie Pang, Chief Scientific Officer

COMBINING THE BEST IN FAT AND IRON



A Multiparametric Analysis of
Liver Tissue Composition
Combining FerriSmart and HepaFat-AI

Report No: EJNWA3xhhAABGmNMZBXQ
Patient ID: 10054136-000017
Name: 10054136-000017
Birth Date:

Scan Date: 12 Aug 2021
Analysis Date: 28 Oct 2021
Referrer:
MRI Center:

SUMMARY OF RESULTS

Average Liver Iron Concentration

2.0 mg/g dry tissue
[95% CI: 1.5 - 2.8]
(NIR: 0.17 - 1.8)

For further details, see the Liver Iron Concentration Report

Liver Fat Assessment

	Result	95% CI (Confidence Interval)	Normal Range
VLFF (Volumetric Liver Fat Fraction)	2.8%	2.2 - 3.6	0 - 4.1
PDFF (Proton Density Fat Fraction)	3.3%	2.6 - 4.3	0 - 4.8
Steatosis Grade	0		0

For further details, see the Liver Fat Assessment Report



Liver Iron Concentration Report

Patient ID: 10054136-000017
Name: 10054136-000017
Birth Date:


Scan Date: 12 Aug 2021
Analysis Date: 28 Oct 2021
Referrer:
MRI Center:

Average Liver Iron Concentration:

2.0 mg/g dry tissue
[95% CI: 1.5 - 2.8]
(NIR: 0.17 - 1.8)

37 mmol/kg dry tissue
[95% CI: 26.6 - 50.2]
(NIR: 1 - 33)

The 95% confidence intervals (95% CI) are derived from a study of rapid measurements by Di Piero et al., *Hepatology* 2018; 67: 188
Normal range (NIR) is taken from Bouchet et al., *Hepatology* 1984; 8: 24-29



Liver Iron Concentration thresholds in Transferrin Iron Overload

Extract from Olivieri et al., *Blood* 1997;89, 739-41

LIC Range	Clinical Relevance
0.1 - 1.0 mg/g dry tissue	Normal range in non-disease patients in healthy population
1.1 - 2.0 mg/g dry tissue	Suggested optimal range of LIC for chelation therapy in transferrin iron loading
2.1 - 3.0 mg/g dry tissue	Increased risk of complications
3.1 - 4.0 mg/g dry tissue	Considered increased risk of cardiac disease and early death in patients with transferrin iron overload

If you have questions on the current analysis result and/or slice selected, please contact Resonance Health at support@resonancehealth.com

Resonance Health Analysis Services Pty Ltd CONFIDENTIAL www.resonancehealth.com



Liver Fat Assessment Report



Patient ID: 10054136-000017
Name: 10054136-000017
Birth Date:

Scan Date: 12 Aug 2021
Analysis Date: 28 Oct 2021
Referrer:
MRI Center:

	Result	95% CI (Confidence Interval)	Normal Range
VLFF (Volumetric Liver Fat Fraction)	2.8%	2.2 - 3.6	0 - 4.1
PDFF (Proton Density Fat Fraction)	3.3%	2.6 - 4.2	0 - 4.8
Steatosis Grade	0		0

The normal VLFF range is derived from direct comparison between MLI measurements and NASH-CRN grading of biopsy (Di Piero et al., *Hepatology* 2018; 67: 188).
The normal PDFF range is derived from the correlation between MLI and PDFF measurements.
The normal NASH-CRN grading is derived from the correlation between MLI and NASH-CRN grading (Di Piero et al., *Hepatology* 2018; 67: 188).

NASH-CRN Steatosis Grading Guide
0 Involvement by steatosis in < 5% of hepatocytes
1 Involvement by steatosis in 5 to 33% of hepatocytes
2 Involvement by steatosis in 33 to 66% of hepatocytes
3 Involvement by steatosis in > 66% of hepatocytes



The Liver Fat Distribution Map is a guide to illustrate the distribution of fat in the liver. The color display is relevant to the liver region only and colors outside the liver are not related to fat content. The color rating table is specific to each individual case. It should not be used for diagnostic purposes.

If you have questions on the current analysis result and/or slice selected, please contact Resonance Health at support@resonancehealth.com

Resonance Health Analysis Services Pty Ltd CONFIDENTIAL www.resonancehealth.com

“LiverSmart is an evolution of our existing product offering and responds to the growing trend in medical imaging for a more holistic assessment of human organs. We have used artificial intelligence to evolve our products to achieve rapid turnaround and enhanced scalability.” - Chad Tondut, GM Projects & Portfolio

3. PROLIFIC (AND GROWING) DISEASES

Deployed Products

Product	Product description	Main Diseases	Disease Prevalence*
 MRI Measurement of Liver Iron Concentration	- Measures liver iron concentration (LIC) - Manual analysis by trained personnel - Global gold standard for LIC measurement	- Thalassaemia - Sickle cell diseases - Heamochromotosis	330K births annually 100K patients in the USA 2M cases in US, 3.7M in EU
 Powered by Resonance Health	- Measures liver iron concentration (LIC) - Automated and instantaneous AI analysis - Calibrated against gold standard FerriScan	- Thalassaemia - Sickle cell diseases - Heamochromotosis	330K births annually 100K patients in the USA 2M cases in US, 3.7M in EU
 MRI Measurement of Liver Fat	- Maps and measures liver fat metrics - Volumetric Liver Fat Fraction (VLFF) - Manual analysis by trained personnel	- NAFLD - NASH - Metabolic diseases	10-30% of global population 25% of NAFLD patients 415m people globally with diabetes
 Powered by Resonance Health	- Maps and measures liver fat metrics - Automated & instantaneous AI analysis - Provides PDF, VLFF, and steatosis grade	- NAFLD - NASH - Metabolic diseases	10-30% of global population 25% of NAFLD patients 415m people globally with diabetes
	- Measures heart iron concentration - Manual analysis by trained personnel - Standardised and controlled analysis	- Thalassaemia - Sickle cell diseases - Heamochromotosis	330K births annually 100K patients in the USA 2M cases in US, 3.7M in EU
	- Measures iron level in bone marrow - Manual analysis by trained personnel - Standardised and controlled analysis	- Cancer - Thalassaemia, Sickle cell diseases - Heamochromotosis	50K BM transplants annually 330K births annually (thal) 2M cases in US, 3.7M in EU
	- T1 and ECV mapping of MRI scanners - Manufactured and shipped by personnel - Quality assurance standardisation device	N/A	36,000 MRI scanners globally 2,500 scanners produced annually - Ratios vary from country to country

* These estimates have been sourced from government sites and international disease advocacy groups.


3. PROLIFIC (AND GROWING) DISEASES

R&D Initiatives

Product	Product description	Main Diseases	Disease Prevalence*
 LiverSmart® Powered by Resonance Health	- Measures liver iron concentration and liver fat - Automated and instantaneous AI analysis - Provides LIC, PDFF, VLFF, and steatosis grade	- Thalassaemia - Sickle cell diseases - Heamochromotosis - NAFLD and NASH - Metabolic diseases	330K births annually 100K patients in the USA 2M cases in US, 3.7M in EU 10-30% of global population 415m people globally with diabetes
 Alert-PE® Powered by Resonance Health	- Uses AI to triage or identify/quantify PE - Automated and instantaneous AI analysis - Provides volumetric analysis of total PE	- Pulmonary embolism - Blood clots in lungs	900K people annually in the USA - Up to 1-2 people per 1000 in the USA 60-100K deaths annually in the USA
 LungSmart	- Measures various lung diseases states - Bronchiectasis, total airways disease - Automated and instantaneous AI analysis	- Cystic fibrosis - Bronchiectasis - Aspiration pneumonia	70K people globally with CF 350-500K annually in USA 1 in 2-3000 GA cases
 CardiacT2* AI	- Measures heart iron concentration - Automated and instantaneous AI analysis - Standardised and controlled test	- Thalassaemia - Sickle cell diseases - Heamochromotosis	330K births annually 100K patients in the USA 2M cases in US, 3.7M in EU
 ASONProject	- Antisense oligonucleotide (ASO) RNA - ASOs targeting 3 cyclophilin proteins 3 patents applications filed	- Viral liver disease - NAFLD and NASH - Liver fibrosis and cancer	2.3 billion with viral liver diseases 10-30% of global population 6-7% of the global population
 BloodMarkerProject	- Novel blood markers to measure iron - Patent filed covering this approach - Alternative to routine Ferritin analysis	- Thalassaemia - Sickle cell diseases - Heamochromotosis	330K births annually 100K patients in the USA 2M cases in US, 3.7M in EU
 FibrosisAssessment	- Novel approach to diagnosing fibrosis - Utilises MRI calibrated with biopsy - More prevalent in iron overload patients	- Fibrosis and Cirrhosis - Liver Cancer - NASH	6-7% of the global population - Most people unaware they have fibrosis - Stage 3 fibrosis is precursor to cirrhosis

* These estimates have been sourced from government sites and international disease advocacy groups.

4. HIGH IMPACT INNOVATION & R&D - NEAR TERM



3T SCANNER CALIBRATION:

- FerriScan and FerriSmart currently only works on 1.5T MRI scanners
- Acquisition protocols being calibrated to 3T MRI scanners
- 3T Scanners becoming more prevalent in hospitals and scanning centres


SHORTER ACQUISITION:

- Decreasing acquisition scanning time for FerriScan and FerriSmart
- Shorter sequences being verified on both 1.5T and 3T scanners
- Reduces patient time in scanner, improves throughput for radiology

“Just as reducing scanner acquisition time from 29 minutes to 9 minutes was significant for FerriScan several years ago, so too will be a further reduction from 9 minutes to under 3 minutes. This will be especially beneficial for our younger patients who will require less time in the scanning machine.”






- Nicholas Allan, Chief Operating Officer

4. HIGH IMPACT INNOVATION & R&D - MEDIUM TERM



- ALERT-PE:**
- AI review of computed tomography (CTPA) scans for suspected pulmonary embolism (PE)
 - CADe tool helps radiologists for moer accurate diagnosis outcome and better patient management
 - Training performed via collaboration with Perth Radiological Clinic
- LungSmart (CF):**
- Licence agreement with Telethon Kids Institute and Erasmus University Medical Centre
 - Automated assessment of lung disease progression in patients with lung conditions, including CF
 - Standardises and automates the detection and quantification of lung diseases
- Cardiac T2* AI:**
- Second biggest product by revenue and by volume of product sales
 - Especially important in developing world where iron overload can spill into the heart
 - Adapation of AI will fully automate the analysis and allow it to be bundled with other AI products
- FAST Upgrade:**
- FAST is the Company's job receipt management and report distribution software
 - Two software developers, including a CTO, recently recruited by the Company
 - Data is now being collected and design is underway for FAST portal rebuild

4. HIGH IMPACT INNOVATION & R&D - LONGER TERM



ASON Project:

- Investigating Antisense Oligonucleotides (ASOs) as a treatment of human diseases
- Using a cell model of the liver in mice, ASOs blocked human proteins critical to viral replication


Liver Iron Marker:

- Pursuing alternative biochemical methods to diagnose iron overload where access to MRI is limited
- Utilising expertise and datasets from existing core products to develop new technique

Fibrosis Assessment:

- Developing a novel non-invasive MRI method to assess liver fibrosis
- Additional service centre personnel recruited to assist with project

WELL BALANCED PORTFOLIO



20/21 FY RESULTS (CASH AT 30/6)

**\$3.78M
REVENUE**

**\$8.86M
CASH
BALANCE**

**\$0.6M*
NPAT**

- Revenue for the FY 20/21 was \$3.78m, an increase of 3% versus the previous year
- Cash on hand at 30 June 2021 of \$8.86m, versus \$6.97m the previous year. The company has no debt
- Net profit after tax of \$585,858, versus a net loss of \$715,000 from the previous year

EXPERIENCED AND QUALIFIED TEAM

Board

- | | |
|---------------------|------------------------|
| • Dr Martin Blake | Non-executive Chairman |
| • Mr Simon Panton | Non-executive Director |
| • Dr Travis Baroni | Non-executive Director |
| • Mr Mitchell Wells | Managing Director |

Executive

- | | |
|---------------------|--------------------------|
| • Mitchell Wells | Managing Director |
| • Nicholas Allan | COO & CFO |
| • Virginia Atkinson | GM Quality & Regulatory |
| • Dr Sherif Boulos | CSO - Molecular |
| • Narelle Mounsey | GM People & Culture |
| • Ajay Nair | Chief eXperience Officer |
| • Prof. John Olynyk | Chief Medical Officer |
| • Dr Wenjie Pang | CSO - AI & Imaging |
| • Chad Tondut | GM Projects & Portfolio |
| • Ben Winters | Chief Technology Officer |

INVESTORS OVERVIEW

LARGEST SHAREHOLDERS (AS OF 24 NOVEMBER 2021)

Rank	Name	Units	% of Units
1	SOUTHAM INVESTMENTS 2003 PTY LTD	73,300,000	15.89
2	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	44,285,296	9.60
3	ACUITY CAPITAL INVESTMENT MANAGEMENT PTY LTD	20,000,000	4.33
4	MS ALISON VIRGINIA WESLEY	10,000,000	2.16
5	MR PAUL JOHN VAN DYK	9,453,700	2.05
6	MR WILLIAM MURRAY THOMPSON	6,658,660	1.44
7	MS JADE LOUISE THOMPSON	6,512,759	1.41
8	DR MARTIN PETER BLAKE	6,464,677	1.40
9	MR BRUCE ALAN STEVENSON	6,400,000	1.38
10	MR HELMUT ROCKER	6,250,000	1.35
11	MR ROBERT FRANCIS PANTON	5,440,824	1.18
12	MARCOLONGO NOMINEES PTY LTD (MARCOLONGO FAMILY A/C)	5,186,200	1.12
13	THE MAJOBRI HOLDINGS PTY LTD (THE MAJOBRI FAMILY A/C)	4,500,000	0.97
14	MR THOMAS PSARAKIS	4,434,777	0.96
15	BNP PARIBAS NOMINEES PTY LTD	4,404,565	0.95
16	MR HARISH GARG	4,001,245	0.86
17	MR VINCENT OLADELE	3,708,052	0.80
18	FULLERTON PRIVATE CAPITAL PTY LIMITED	3,500,000	0.75
19	THE UNIVERSITY OF WESTERN AUSTRALIA	3,478,750	0.75
20	MORGAN STANLEY AUSTRALIA	3,460,176	0.75
		231,439,681	50.18



INVESTOR PRESENTATION

Resonance Health (ASX: RHT) is an Australian healthcare company specialising in the development and delivery of non-invasive medical imaging software and analysis services.

141 Burswood Road, Burswood WA 6100
Telephone: +61 (0)8 9286 5300
Fax: +61 8 9286 5399
E-mail: info@resonancehealth.com